Efficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms

Epilepsy Research

Volumn 108, Issue 1, 2014, Pages 98-108

  Jequier Gygax, Marine ^a,b   Klein, Brian D ^c,d   White, H Steve ^d   Kim, Mimi ^a   Galanopoulou, Aristea S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c NeuroAdjuvants Inc   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Antibody; Antiepileptic; Cerebral cortex; Galanin receptor; Glucose; Neurodevelopmental reflexes

Indexed keywords

ANTICONVULSIVE AGENT; GALANIN RECEPTOR 1; GALANIN RECEPTOR 2; GLUCOSE; MESSENGER RNA; NAX 5055; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GALR1 GENE; GALR2 GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART RATE; HIPPOCAMPUS; INFANTILE SPASM; MALE; NONHUMAN; OXIMETRY; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; RECEPTOR GENE; SINGLE DRUG DOSE;

ACTH; ADRENOCORTICOTROPIC HORMONE; ANTIBODY; ANTIEPILEPTIC; CEREBRAL CORTEX; GALANIN RECEPTOR; GALR; GLUCOSE; I.P.; INFANTILE SPASMS; INTRAPERITONEAL; IS; NEGATIVE GEOTAXIS; NEURODEVELOPMENTAL REFLEXES; NG; OFA; OPEN FIELD ACTIVITY; PN; POSTNATAL DAY; SRT; SURFACE RIGHTING TIME;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; EPILEPSY; FEMALE; GALANIN; MALE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; SPASM; TREATMENT OUTCOME;

EID: 84890786078     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.10.015     Document Type: Article

References (43)

1. Abbott S.B., Pilowsky P.M. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296(4):R1019-R1026.
2. Abbott S.B., Burke P.G., Pilowsky P.M. Galanin microinjection into the PreBotzinger or the Botzinger Complex terminates central inspiratory activity and reduces responses to hypoxia and hypercapnia in rat. Respir. Physiol. Neurobiol. 2009, 167(3):299-306.
3. Badie-Mahdavi H., Lu X., Behrens M.M., Bartfai T. Role of galanin receptor 1 and galanin receptor 2 activation in synaptic plasticity associated with 3',5'-cyclic AMP response element-binding protein phosphorylation in the dentate gyrus: studies with a galanin receptor 2 agonist and galanin receptor 1 knockout mice. Neuroscience 2005, 133(2):591-604.
4. Bartfai T., Lu X., Badie-Mahdavi H., Barr A.M., Mazarati A., Hua X.Y., Yaksh T., Haberhauer G., Ceide S.C., Trembleau L., Somogyi L., Krock L., Rebek J.J. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(28):10470-10475.
5. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010, 92(2-3):89-124.
6. Bulaj G., Green B.R., Lee H.K., Robertson C.R., White K., Zhang L., Sochanska M., Flynn S.P., Scholl E.A., Pruess T.H., Smith M.D., White H.S. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J. Med. Chem. 2008, 51(24):8038-8047.
7. Burazin T.C., Larm J.A., Ryan M.C., Gundlach A.L. Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. Eur. J. Neurosci. 2000, 12(8):2901-2917.
8. Chudomelova L., Scantlebury M.H., Raffo E., Coppola A., Betancourth D., Galanopoulou A.S. Modeling new therapies for infantile spasms. Epilepsia 2010, 51(Suppl. 3):27-33.
9. Crawley J.N. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. Cell. Mol. Life Sci. 2008, 65(12):1836-1841.
10. Darke K., Edwards S.W., Hancock E., Johnson A.L., Kennedy C.R., Lux A.L., Newton R.W., O'Callaghan F.J., Verity C.M., Osborne J.P. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch. Dis. Child. 2010, 95(5):382-386.
11. Diaz-Cabiale Z., Parrado C., Vela C., Razani H., Covenas R., Fuxe K., Narvaez J.A. Role of galanin and galanin(1-15) on central cardiovascular control. Neuropeptides 2005, 39(3):185-190.
12. Galanopoulou A.S. Basic mechanisms of catastrophic epilepsy - overview from animal models. Brain Dev. 2013, 35(8):748-756.
13. Gregersen S., Langel U., Bartfai T., Ahren B. N-terminally elongated fragments of galanin(1-16) inhibit insulin secretion from isolated mouse islets. Regul. Pept. 1994, 53(1):31-37.
14. Haberman R.P., Samulski R.J., McCown T.J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 2003, 9(8):1076-1080.
15. Hermansen K. Effects of galanin on the release of insulin, glucagon and somatostatin from the isolated, perfused dog pancreas. Acta Endocrinol. (Copenh.) 1988, 119(1):91-98.
16. Kivity S., Lerman P., Ariel R., Danziger Y., Mimouni M., Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004, 45(3):255-262.
17. Kocic I. The influence of the neuropeptide galanin on the contractility and the effective refractory period of guinea-pig heart papillary muscle under normoxic and hypoxic conditions. J. Pharm. Pharmacol. 1998, 50(12):1361-1364.
18. Lindskog S., Gregersen S., Hermansen K., Ahren B. Effects of galanin on proinsulin mRNA and insulin biosynthesis in normal islets. Regul. Pept. 1995, 58(3):135-139.
19. Lombroso C.T. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983, 24(2):135-158.
20. Lu X., Bartfai T. Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn. Schmiedebergs Arch. Pharmacol. 2009, 379(4):417-420.
21. Lu X., Roberts E., Xia F., Sanchez-Alavez M., Liu T., Baldwin R., Wu S., Chang J., Wasterlain C.G., Bartfai T. GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(34):15229-15234.
22. Lux A.L., Edwards S.W., Hancock E., Johnson A.L., Kennedy C.R., Newton R.W., O'Callaghan F.J., Verity C.M., Osborne J.P. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004, 364(9447):1773-1778.
23. Mackay M.T., Weiss S.K., Adams-Webber T., Ashwal S., Stephens D., Ballaban-Gill K., Baram T.Z., Duchowny M., Hirtz D., Pellock J.M., Shields W.D., Shinnar S., Wyllie E., Snead O.C.r. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004, 62(10):1668-1681.
24. Mazarati A.M. Galanin and galanin receptors in epilepsy. Neuropeptides 2004, 38(6):331-343.
25. Mazarati A., Langel U., Bartfai T. Galanin: an endogenous anticonvulsant?. Neuroscientist 2001, 7(6):506-517.
26. Mazarati A., Lundstrom L., Sollenberg U., Shin D., Langel U., Sankar R. Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype-selective agonists and the role of G-protein-mediated signaling. J. Pharmacol. Exp. Ther. 2006, 318(2):700-708.
27. Mazarati A.M., Hohmann J.G., Bacon A., Liu H., Sankar R., Steiner R.A., Wynick D., Wasterlain C.G. Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 2000, 20(16):6276-6281.
28. Melander T., Hokfelt T., Rokaeus A., Cuello A.C., Oertel W.H., Verhofstad A., Goldstein M. Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J. Neurosci. 1986, 6(12):3640-3654.
29. Mitsukawa K., Lu X., Bartfai T. Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1. Neuroscience 2009, 160(4):837-846.
30. O'Callaghan F.J., Lux A.L., Darke K., Edwards S.W., Hancock E., Johnson A.L., Kennedy C.R., Newton R.W., Verity C.M., Osborne J.P. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011, 52(7):1359-1364.
31. Ono T., Moshe S.L., Galanopoulou A.S. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. Epilepsia 2011, 52(9):1678-1684.
32. Patel S., Hutson P.H. Effects of galanin on 8-OH-DPAT induced decrease in body temperature and brain 5-hydroxytryptamine metabolism in the mouse. Eur. J. Pharmacol. 1996, 317(2-3):197-204.
33. Paxinos G., Ashwell K.W.S., Tork I. Atlas of the Developing rat Nervous System 1994, Academic Press, San Diego, CA.
34. Pellock J.M., Hrachovy R., Shinnar S., Baram T.Z., Bettis D., Dlugos D.J., Gaillard W.D., Gibson P.A., Holmes G.L., Nordl D.R., O'Dell C., Shields W.D., Trevathan E., Wheless J.W. Infantile spasms: a U.S. consensus report. Epilepsia 2010, 51(10):2175-2189.
35. Raffo E., Coppola A., Ono T., Briggs S.W., Galanopoulou A.S. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol. Dis. 2011, 43(2):322-329.
36. Riikonen R. ACTH therapy of West syndrome: finnish views. Brain Dev. 2001, 23(7):642-646.
37. Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev. 2001, 23(7):683-687.
38. Riikonen R.S. Favourable prognostic factors with infantile spasms. Eur. J. Paediatr. Neurol. 2010, 14(1):13-18.
39. Robertson C.R., Scholl E.A., Pruess T.H., Green B.R., White H.S., Bulaj G. Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. J. Med. Chem. 2010, 53(4):1871-1875.
40. Ruczynski J., Cybal M., Wojcikowski C., Rekowski P. Effects of porcine galanin, galanin(1-15)NH2 and its new analogues on glucose-induced insulin secretion. Pol. J. Pharmacol. 2002, 54(2):133-141.
41. Scantlebury M.H., Galanopoulou A.S., Chudomelova L., Raffo E., Betancourth D., Moshe S.L. A model of symptomatic infantile spasms syndrome. Neurobiol. Dis. 2010, 37(3):604-612.
42. Verchere C.B., Kwok Y.N., Brown J.C. Stimulus-specific inhibition of insulin release from rat pancreas by both rat and porcine galanin. Life Sci. 1992, 51(25):1945-1951.
43. White H.S., Scholl E.A., Klein B.D., Flynn S.P., Pruess T.H., Green B.R., Zhang L., Bulaj G. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models. Neurotherapeutics 2009, 6(2):372-380.